We believe that being transparent about our support for patient groups, our charitable giving and payments to healthcare professionals helps build trust with our stakeholders. Read about our disclosure below.
Patient group funding
We publish information on all our work with patient groups, including details of the funding received. See details of our funding for patient organisations in the UK.
We are transparent about our charitable giving with data published in our Annual Report and Corporate Responsibility Report each year. We also publish details of our individual charitable grants over £10,000 ($20,000).
Payments to UK healthcare professionals
GSK is a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. Our products are used by millions of people around the world, helping them to do more, feel better and live longer. With our headquarters in the UK, we have a wide geographical reach. We have offices in more than 115 countries, major research centres in the UK, USA, Spain, Belgium and China and an extensive manufacturing network with 87 sites globally.
GSK is the largest pharmaceutical company by value in the UK. We employ more than 15,000 people across 16 sites. We currently have more than 90 branded prescription medicines in our UK portfolio, spanning 7 therapy areas.
Doctors and other healthcare professionals (HCPs) are valuable partners for GSK, providing us with scientific and medical expertise and insights into patient care. We believe this partnership is fundamental to the progress of medical science and to help meet patient and public health needs.
We believe that HCPs and healthcare organisations that we work with should be fairly compensated for the services and expertise they provide to us. However, payments must not be excessive and must never be an inducement or reward for prescribing our products. We have clear standards, aligned to international and regional codes of practice and appropriate country laws and regulations, which govern these payments and help safeguard against this risk.
GSK’s consultancy payments to HCPs, sponsorships to attend scientific meetings and congresses, and grants and donations to healthcare organisations in the UK are made in line with the Association of British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry.
In 2011, along with a number of other leading healthcare companies in the UK, GSK signed a joint statement through the ABPI committing to the reporting of payments to UK HCPs and sponsorship of UK HCPs to attend scientific meetings and congresses, annually at an aggregate level. It also committed to the reporting of grants and donations to named healthcare organisations.
The ABPI has produced a leaflet which further explains the public declaration of payments to healthcare professionals.
See details of our 2012 payments to HCPs and grants and donations to healthcare organisations in the UK.